ClinicalTrials.gg
Not yet recruitingNCT07949942Updated Nov 19, 2026

SNAP Trial - Phage Domain (Domain I)

A Phase 2/3 interventional study of Intravenous S. aureus phage cocktail and Placebo in Staphylococcal Aureus Infection, sponsored by University of Melbourne. Not yet recruiting at 11 sites in Australia. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Melbourne · Phase 2/3, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
270
Allocation
Randomized
Sex
All
01

Study summary

This is a domain of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial.

The SNAP Trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions for patients with Staphylococcus Aureus bacteraemia (SAB). The SNAP Trial clinicaltrials.gov listing is NCT05137119.

The University of Melbourne is the Global Coordinating Centre for the SNAP Trial; each participating region will have their own sponsor who will maintain responsibility for trial activities in their region.

Read the detailed description

The primary objective is to evaluate the impact of adjunctive phage therapy in clearing the bloodstream infection in SAB.

Secondary objectives are to determine:

  1. The safety and tolerability of adjunctive phage therapy used in patients with persistent SAB
  2. Bacterial (evolving anti-phage resistance) and human host (evolving adaptive immunity) responses to adjunctive phage therapy Maximum recruitment is 270 participants, allocated at random to placebo and phage therapy in a 1:1 ratio. The primary outcome is at least one positive blood culture collected 44-76 hours after domain entry. The primary analysis uses a Bayesian logistic model and there is one interim analysis after 70% of randomised participants have reached the end of the follow up period for the primary endpoint.
02

Conditions studied

  • Staphylococcal Aureus Infection

Keywords

  • Staphylococcus aureus
  • S. aureus
  • SNAP Trial
  • Staph Aureus Bacteremia (SAB)
  • phage
  • phage treatment
  • bacteriophage
03

In context

Staphylococcal Infections

305 studies on the registry are indexed under Staphylococcal Infections; 36 are open to participants now.

This study's planned enrollment of 270 is above the median of 124 across 199 interventional studies indexed under Staphylococcal Infections.

Browse Staphylococcal Infections studies →

Lead sponsor

University of Melbourne is the lead sponsor of 87 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 48 hours of confirmed SAB - defined as two positive blood cultures obtained at least 48 hours apart
  2. Intravenous S. aureus phage cocktail (and placebo) available and able to be dispensed and administered within 24 hours of domain entry

Exclusion criteria

Exclusion Criteria:

  1. History of or known intolerance or to intravenous S. aureus phage cocktail (JIPh_Sau300 or JIPh_Sau301) or its
  2. Patient weight under 4kg
  3. Treating team deems enrolment in this domain is not in the best interests of the patient (provide reason)
  4. At the time of domain eligibility assessment and consent, more than 3 days has elapsed since platform entry
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Adjunctive Phage Therapy (Intravenous S. aureus phage cocktail [JIPh_Sau300 and JIPh_Sau301])

    1mL of 1x 1010 plaque forming units (PFU) of each phage will be administered intravenously (IV), twice a day for 5 days (10 doses). Both phages will be supplied to hospital pharmacies in separate vials. 1mL of each phage will be drawn from supplied vials and both added to a bag of 50mL (or 100mL) of 0.9% normal saline and administered IV over 10-15 minutes (or up to 30 minutes if a slower infusion is required).

    Drug: Intravenous S. aureus phage cocktail

  • Placebo comparator
    Placebo (Intravenous normal (0.9%) saline)

    52mL (or 102mL) administered IV, twice a day for 5 days (10 doses) over 10-15 minutes (or up to 30 minutes if a slower infusion is required). Study medication should be made up in the pharmacy in normal saline as close to the timing of administration as possible.

    Other: Placebo

Interventions

  • DrugIntravenous S. aureus phage cocktail

    JIPh\_Sau300 and JIPh\_Sau301

  • OtherPlacebo

    Intravenous normal \[0.9%\] saline

06

What researchers measure

Primary outcomes

  1. Positive blood culture 44-76 hours after domain entry

    At least one positive blood culture collected 44-76 hours after domain entry.

    Time frame: From domain entry until 46-76 hours after domain entry

Secondary outcomes

  1. Duration of bacteraemia

    Defined as days from domain entry until date of collection of the first negative blood culture for S. aureus, censored at platform day 14

    Time frame: From domain entry, censored at platform day 14

  2. In vitro resistance against one or more of the phages

    In vitro resistance against one or more of the phages included in the intervention that occurs in the final S. aureus isolate obtained from a blood culture from a participant in the phage therapy arm only (not placebo arm), where the index blood culture from the participant at platform entry demonstrated susceptibility to the same phage.

    Time frame: Platform day 90

  3. Serum neutralisation (antiphage antibody) against one or more of the phages

    Serum neutralisation (antiphage antibody) against one or more of the phages included in the intervention, that was not present on a blood sample collected at domain entry, and that develops on any serum sample obtained from domain entry until the end of platform day 14 or until total discharge (censored at day 31), whichever occurs last, in a participant in the active phage therapy arm and in around 10% of participants in the placebo arm, selected randomly. Total discharge is defined as the timepoint when the participant has 1) Ended their initial hospital admission to any acute inpatient facility, including HITH/OPAT/COPAT and stepdown inpatient rehabilitation/post-acute care (if continuous with the initial admission to a SNAP-enrolling hospital) AND 2) Ended their IV antibiotic treatment for SAB

    Time frame: From domain entry until the end of platform day 14 or until total discharge (censored at day 31), whichever occurs last

  4. Serious Adverse Events (SAEs)

    SAEs that occur from domain entry until the end of platform day 14.

    Time frame: From platform entry until day 14

  5. At least one occurrence of a clinically significant change (worsening)

    At least one occurrence of a clinically significant change (worsening) in 2 or more of heart rate (HR), respiratory rate (RR), temperature, blood pressure (BP) from a pre-dose baseline, occurring up to 12 hours following any dose of study medication, as assessed by a treating clinician.

    Time frame: From platfrom entry until day 90

  6. LFT Derangement

    LTF derangement defined as: 1. Grade 2 or above increase in ALT and/or GGT (\>2.5x ULN), which was not present on any blood sample collected within 24 hours of domain entry occurring from platform day 5 (+/-1 day) until the end of platform day 14 or until acute discharge, whichever occurs first; or 2. \>2.5x increase in enzyme levels in those with abnormal results at (or within 24 hours of) domain entry, occurring from platform day 5 (+/-1 day) until the end of platform day 14 or until acute discharge, whichever occurs first. or 3. If ALT and GGT are unknown at (or within 24 hours of) domain entry, ≥5x ULN in ALT and/or GGT occurring from platform day 5 (+/-1 day) until the end of platform day 14 or until acute discharge, whichever occurs first. Acute discharge is defined as the timepoint when the participant has ended their hospital admission at an acute inpatient facility, at either the primary site or secondary acute care site (if continuous with the initial admission).

    Time frame: From domain entry until day 90 or acute discharge, whichever occurs first

Other outcomes

  1. Core Secondary Endpoint: All-cause mortality 90 days after platform entry

    Only specified core protocol outcomes (listed in NCT05137119) apply to this domain as secondary endpoints.

    Time frame: From platform entry until day 90

  2. Core Secondary Endpoint: All-cause mortality 28 days after platform entry

    Only specified core protocol outcomes (listed in NCT05137119) apply to this domain as secondary endpoints.

    Time frame: From platform entry until day 28

  3. Core Secondary Endpoint: All-cause mortality 42 days after platform entry

    Only specified core protocol outcomes (listed in NCT05137119) apply to this domain as secondary endpoints.

    Time frame: From platform entry until day 42

  4. Core Secondary Endpoint: Time to being discharged alive from the total index hospitalisation (including HITH/COPAT/OPAT/rehab)

    Only specified core protocol outcomes (listed in NCT05137119) apply to this domain as secondary endpoints.

    Time frame: From platform entry to total discharge, truncated at 90 days

  5. Core Secondary Endpoint: Serious adverse reactions possibly, probably or definitely attributable to an intervention in the phage domain

    Only specified core protocol outcomes (listed in NCT05137119) apply to this domain as secondary endpoints.

    Time frame: From platform entry until day 90

07

Study locations

11 sites
08

References and documents

Individual participant data

Plan to share: Yes — All requests for data sharing must be accompanied by a SNAP data access request from, a study proposal with clear statement of aims and hypotheses, and a statistical analysis plan. All applications will be assessed by the SNAP Trial Steering Committee. Applications from investigators with suitable academic capability to conduct the proposed work will be given consideration. If a proposal is approved, a signed data transfer agreement will be required before data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: IPD and supporting information will be available 12 months after the publication of the primary results manuscript and will be available for a 10 year period.

Data sharing details ↗ · www.snaptrial.com.au

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 19, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949942
Lead sponsor
University of Melbourne
Collaborators
Westmead Institute for Medical Research, University of Sydney, Sydney Children's Hospitals Network
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

SNAP Global Trial Manager(s)
Contact
snap-trial@unimelb.edu.au
+61 (0) 38344 7739
Phage Therapy Domain Manager(s)
Contact
admin-sabrephi.trial@sydney.edu.au
Ameneh Khatami
study chair · University of Sydney
Jonathan Iredell
study chair · The Westmead Institute for Medical Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion